Rhythm Pharmaceuticals Inc To Discuss Hypothalamic Obesity Call Transcript
And thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Connolly, with Rhythm Pharmaceuticals. Please go ahead.
Yes, thank you, and thank you all for joining us today. For those participating via the conference call, there are accompanying slides that can be accessed and controlled by going to the Events section of our Investors page on our website at ir.rhythmtx.com.
This morning, we announced positive interim results from our Phase II clinical trial evaluating setmelanotide in hypothalamic obesity via a press release, which is now available on our website.
On the conference call today, as listed on Slide 2 on the agenda, are Dr. David Meeker, Rhythm Chair, Chief Executive Officer and President; Dr. Jennifer Abuzzahab, a pediatric endocrinologist at the McNeely
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
